Psilera Inc., a biopharmaceutical company optimizing next-generation mental health treatments, announces the patent approval of N,N-dimethyltryptamine (DMT) and psilacetin (4-AcO-DMT and psilocybin-like prodrug) transdermal patch formulations. Transdermal application allows patients to dose topically while receiving treatment through the surface of their skin, overcoming the need for intravenous needles and episodic oral dosing. This patient-first approach may…